Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Whether plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels is a predictor for cardiovascular outcomes has currently been controversial. No data is currently available regarding the relation of PCSK9 to cardiovascular metabolic markers (CVMMs) and major adverse cardiovascular events (MACEs) in stable coronary artery disease (CAD) patients with diabetes or without diabetes.
Methods: A total 1225 untreated patients with stable CAD were consecutively enrolled and their baseline plasma PCSK9 levels were determined by ELISA. Patients were divided into high and low PCSK9 groups according to PCSK9 median. All patients followed up for the occurrence of MACEs and received standard therapy after admission. The associations of PCSK9 with CVMMs and MACEs were evaluated.
Results: PCSK9 levels were positively correlated with multiple CVMMs including total cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and hemoglobin A at baseline (all p < 0.05). During a median follow-up of 3.3 years, 103 (8.4%) events occurred. PCSK9 levels were higher in patients with events compared to those without (p < 0.05). The Kaplan-Meier analysis displayed that patients in high PCSK9 group had lower event-free survival than that in low group (p < 0.05). Multivariable Cox regression analysis revealed that PCSK9 levels were independently associated with MACEs in diabetic patients (adjusted hazard ratio [HR]: 1.361, 95% confidence interval [CI]: 1.037-1.785, p < 0.05). When added the combination of PCSK9 levels and diabetic status to stratifying factors, patients in high PCSK9 group appeared to have extremely high risk of subsequent MACEs with diabetes (adjusted HR: 5.233, 95% CI: 2.546-10.757, p < 0.01).
Conclusions: The present study firstly showed that elevated PCSK9 levels were related to multiple CVMMs and MACEs in stable CAD with diabetes, suggesting that plasma PCSK9 measurement could help to identify diabetic patients with CAD at higher cardiovascular risk. More studies may be needed to confirm our findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541318 | PMC |
| http://dx.doi.org/10.1186/s12933-020-01142-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic Pathogenesis of Abdominal Aortic Aneurysm and the Role of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9).
Vasc Specialist Int
September 2025
Department of Vascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
An abdominal aortic aneurysm (AAA) is defined as a localized dilation of the abdominal aorta measuring at least 1.5 times its normal diameter. If left untreated, AAA can progress to a life-threatening condition.
View Article and Find Full Text PDFPrevalence and penetrance of pathogenic and likely pathogenic and gene variants linked to familial hypercholesterolemia and increased risk of ischemic heart disease.
Front Genet
August 2025
Federal Medical and Biologicl Agency, Moscow, Russia.
Background: Familial hypercholesterolemia (FH) is a prevalent hereditary disorder, with its monogenic form linked to an elevated risk of early-onset ischemic heart disease. Evaluating the prevalence and penetrance of pathogenic and likely pathogenic variants associated with this disorder would provide valuable information supporting routine FH screening of the general population. Such informed screening would facilitate early identification of at-risk individuals, enabling timely intervention and management.
View Article and Find Full Text PDFFisetin ameliorates atherosclerosis through activating FXR-mediated hepatic cholesterol metabolism and transintestinal cholesterol excretion.
Food Res Int
November 2025
College of Public Health, Zhengzhou University, Zhengzhou, China; Food Laboratory of Zhongyuan, Luohe, Henan, China. Electronic address:
Cholesterol homeostasis dysregulation is a primary risk factor for atherosclerosis (AS) development. Fisetin, a flavonoid compound, has shown promise in regulating cholesterol homeostasis by enhancing transintestinal cholesterol excretion (TICE). This study aimed to investigate the regulatory effects and underlying mechanisms of fisetin in AS.
View Article and Find Full Text PDFVitamin D potentiation of metformin hepatoprotective activities: Concurrent targeting of carbohydrate enzymatic pathways and PCSK9/AGEs-regulated oxidative stress mechanisms in type 2 diabetic male Wistar rats.
Steroids
September 2025
Department of Physiology, University of Ilorin, Ilorin, Nigeria.
Background: Emerging evidence indicates that metformin-based combination therapy may offer better glycemic control and improved tolerability compared to diabetes monotherapy. Building on this, vitamin D was considered a potential adjunct to metformin for managing type 2 diabetes. Although vitamin D is primarily recognized for its role in calcium regulation, it also appears to influence glucose metabolism and other non-skeletal functions.
View Article and Find Full Text PDFLiver-targeted siRNA delivery via artificial red blood cells to lower LDL-C.
Int J Pharm
September 2025
The Fifth Affiliated Hospital, The Affiliated Panyu Central Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Gu
Elevated levels of low-density lipoprotein cholesterol (LDL-C) are a key risk factor contributing to the progression of ischemic heart disease. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) with small interfering RNA (siRNA) provides an alternative therapeutic option for lowering LDL-C levels. However, the poor pharmacokinetic profiles of naked siRNA hinder clinical application.
View Article and Find Full Text PDF